LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Beam Therapeutics Inc. (“Beam” or “the Company”) (NASDAQ : BEAM) for violating securities laws.
The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Beam issued a press release on August 1, 2022, announcing “that on Friday, July 29, 2022, the company was notified by email from the United States Food and Drug Administration (FDA) that BEAM-201 Investigational New Drug (IND) for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL) has been placed on clinical hold. The company added that “the FDA has indicated that it will provide a formal clinical hold letter to Beam within 30 days.” Based on this news, shares of Beam fell sharply in intraday trading.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by email at [email protected]
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.
Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.
This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.